tradingkey.logo

Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia

ReutersApr 30, 2025 11:16 AM

- Amylyx Pharmaceuticals Inc AMLX.O:

  • AMYLYX PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED IN PIVOTAL PHASE 3 LUCIDITY TRIAL OF AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA

  • AMYLYX PHARMACEUTICALS INC - LUCIDITY TRIAL RECRUITMENT EXPECTED TO COMPLETE IN 2025, WITH TOPLINE DATA IN FIRST HALF OF 2026

  • AMYLYX PHARMACEUTICALS INC - EXPECTS CASH RUNWAY THROUGH END OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI